Vertex Pharmaceuticals stock gains focus after 12% revenue growth

Vertex Pharmaceuticals reported third-quarter results on Monday, November 2, 2026, and lifted its full-year outlook. According to the Vertex Pharmaceuticals news release, revenue reached USD 3.44 billion for the period ended September 30, an increase of 12 percent from the third quarter of 2025. Vertex Pharmaceuticals stock traded at 482.50 euros on Lang & Schwarz at 15:09 CET on Wednesday, November 4.

Guidance rises after quarterly growth

Vertex raised its 2026 revenue forecast to USD 13.15 billion to USD 13.25 billion, compared with the previous range of USD 13.1 billion to USD 13.2 billion. The revised outlook includes at least USD 500 million from CASGEVY and JOURNAVX combined, as well as USD 40 million to USD 50 million from PALSONIFY after the Crinetics Pharmaceuticals acquisition.

The acquisition also lifted the expense outlook. Vertex now expects combined non-GAAP research and development, acquired in-process research and development, and selling, general and administrative expenses of about USD 6.0 billion for 2026, up from the former range of USD 5.65 billion to USD 5.75 billion. The company attributed the increase mainly to Crinetics operations and integration.

New products widen the portfolio

Cystic fibrosis medicines remained the main revenue source, with quarterly sales of USD 3.27 billion. Trikafta and Kaftrio revenue declined to USD 2.44 billion from USD 2.65 billion a year earlier, while Alyftrek revenue rose to USD 705.8 million from USD 247.0 million.

Vertex also reported stronger contributions from newer products. CASGEVY revenue rose to USD 99.2 million from USD 16.9 million, JOURNAVX revenue increased to USD 58.3 million from USD 19.6 million, and PALSONIFY contributed USD 10.1 million following the September 1 closing of the Crinetics transaction.

GAAP net income fell to USD 653.6 million from USD 1.08 billion, mainly because of acquisition-related expenses. Non-GAAP net income was USD 1.21 billion, compared with USD 1.24 billion in the prior-year quarter. The company said the adjusted figure was affected by higher operating expenses and financing costs linked to the transaction.

FDA decision sets next catalyst

The next major event is the U.S. FDA target action date of November 30 for povetacicept in IgA nephropathy. Vertex said the application is under priority review and that approval would establish nephrology as its fifth commercial franchise. The company is also advancing the medicine in primary membranous nephropathy and generalized myasthenia gravis.

For investors, the earnings release points to a broader product mix but also to higher spending and integration costs. The revenue increase was supported by established cystic fibrosis products and newer launches, while the upcoming regulatory decision could determine how quickly the renal strategy develops.

The broader market setting remains relevant for biotechnology shares; see Current S&P 500 market coverage.

For more company-specific developments, see the real-time quote of Vertex Pharmaceuticals stock and More news and analyses on Vertex Pharmaceuticals stock.

Vertex Pharmaceuticals overview

• Company: Vertex Pharmaceuticals Incorporated
• ISIN: US92532F1003
• Ticker: VRTX
• Quote: EUR 482.50 on Lang & Schwarz, November 4, 2026, 15:09 CET
• Reporting period: Third quarter ended September 30, 2026
• Revenue: USD 3.44 billion
• FDA milestone: November 30, 2026 target action date for povetacicept in IgA nephropathy